Please login to the form below

Not currently logged in
Email:
Password:

antibody-drug conjugates

This page shows the latest antibody-drug conjugates news and features for those working in and with pharma, biotech and healthcare.

Daily brief: Global Blood confident of sickle cell success, Breathalyser wins engineering award, Swiss biotech raises funds

Daily brief: Global Blood confident of sickle cell success, Breathalyser wins engineering award, Swiss biotech raises funds

into clinical development and additional antibody drug conjugates pipeline programmes.

Latest news

  • Bluebird and Celgene BCMA CAR-T kicks off ASCO Bluebird and Celgene BCMA CAR-T kicks off ASCO

    varlilumab, Forty Seven’s anti-CD47 drug Hu5F9-G4 and CD122-biased agonist NKTR-214 from Nektar, to name just a few. ... mind - and antibody-drug conjugates will also feature prominently.

  • Bayer gets clinical data to support $1.5bn Loxo deal Bayer gets clinical data to support $1.5bn Loxo deal

    In all but one cases the 17 patients have remained on drug therapy or received surgery with the intent of curing the cancer, according to the investigators. ... stage projects in oncogenic signalling, antibody-drug conjugates, targeted thorium conjugates

  • Joerg Moeller to head Bayer R&D after operational shake-up Joerg Moeller to head Bayer R&D after operational shake-up

    The restructuring means Andreas Busch - current head of drug discovery at the German company - is heading for the exit, but has already lined up another senior position at Shire, where he ... drug conjugates, targeted thorium conjugates (TTCs) and

  • Astellas extends phase III programme for Rydapt rival gilteritinib Astellas extends phase III programme for Rydapt rival gilteritinib

    Last month, the drug picked up an orphan drug designation from the FDA. ... It also has a 10-year-plus collaboration with Seattle Genetics covering microtubule-disrupting antibody-drug conjugates.

  • Celgene steps back from $1bn Sutro acquisition Celgene steps back from $1bn Sutro acquisition

    Now Celgene has decided to focus its involvement on four programmes headed to clinical trials - including an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA). ... Our goal is to continue to build momentum for promising antibody

More from news
Approximately 7 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare

    Current projects include developing antibodies for use as cancer imaging agents, antibody drug conjugates, chimeric antigen receptor therapies (CAR-Ts) and nano-medicines. ... and using efficient AI to generate a set of high-quality drug candidates.

  • Deal Watch February 2016 Deal Watch February 2016

    The antibody, to be known as COR-001, will be progressed for cardiovascular applications. ... This month saw two existing partnerships that have been extended. Takeda has been working with Mersana Therapeutics since 2014 to develop antibody drug

  • Pharma deals in April 2015 Pharma deals in April 2015

    The agreement also includes payment of double digit royalties. Innate also put in place a collaboration with Sanofi for next generation antibody-drug conjugates (ADCs) using Innate's site specific conjugation ... its SAR3419, an antibody-drug conjugate

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 150. Sutro Biopharma/Celgene. Licence plus option to acquire Sutro. For development of multispecific antibodies and antibody drug conjugates (ADCs). ... 475. CureTech/Medivation. Exclusive global licence. For pidilizumab (CT-011), an immune modulatory

  • Pharma deals during October 2014 Pharma deals during October 2014

    An oncology deal for multispecific antibodies and antibody drug conjugates [ADCs], this transaction builds on the original deal signed in December 2012 with a headline of $500m. ... Keeping it flexible, Roche extended its 2013 licence agreement with

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Crescendo Biologics appoints Peter Pack as CEO Crescendo Biologics appoints Peter Pack as CEO

    Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody drug conjugate (HDC) therapeutics. ... We intend to expand rapidly our internal oncology programmes on checkpoint modulators and HDCs, which are a

  • ADC Therapeutics expands team ADC Therapeutics expands team

    ADC Therapeutics expands team. Appointments preceed its first antibody drug conjugate trials. ... ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development.

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

  • AVEO's financial head joins ImmunoGen AVEO's financial head joins ImmunoGen

    In his new role, Johnston will head the financial operations of one of the leading biotechs working to develop antibody-drug conjugates in cancer, with ImmunoGen's successes including the breast

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    CytomX Therapeutics has boosted both its senior science and business teams following a major antibody deal with Pfizer. ... Both positions will be crucial to supporting the San Francisco-based biotech's growth following CytomX's  $635m deal agreed with

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics